NLRP3 and liver dysplastic nodule: Recently, Yaribeygi et al. (2019) collected and summarized a large number of studies and found that certain antidiabetic drugs such as SGLT2 inhibitors (Ye et al., 2017; Birnbaum et al., 2018), biguanides (Woo et al., 2014; Li A.Y. et al., 2016), thiazolidinediones (Wang Y. et al., 2017), and DPP-4 inhibitors (Birnbaum et al., 2016) can also modulate NLRP3 inflammasome activity to prevent the development of DN.